JPWO2023176862A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023176862A5 JPWO2023176862A5 JP2024508204A JP2024508204A JPWO2023176862A5 JP WO2023176862 A5 JPWO2023176862 A5 JP WO2023176862A5 JP 2024508204 A JP2024508204 A JP 2024508204A JP 2024508204 A JP2024508204 A JP 2024508204A JP WO2023176862 A5 JPWO2023176862 A5 JP WO2023176862A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- oligonucleotide
- nucleotide
- nucleoside
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022041864 | 2022-03-16 | ||
| PCT/JP2023/009973 WO2023176862A1 (ja) | 2022-03-16 | 2023-03-15 | トランスフェリン受容体２の発現を抑制するｓｉＲＮＡ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023176862A1 JPWO2023176862A1 (https=) | 2023-09-21 |
| JPWO2023176862A5 true JPWO2023176862A5 (https=) | 2026-03-24 |
Family
ID=88023868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508204A Pending JPWO2023176862A1 (https=) | 2022-03-16 | 2023-03-15 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250188478A1 (https=) |
| EP (1) | EP4495240A1 (https=) |
| JP (1) | JPWO2023176862A1 (https=) |
| KR (1) | KR20240161967A (https=) |
| CN (1) | CN118891366A (https=) |
| AU (1) | AU2023234185A1 (https=) |
| CO (1) | CO2024013601A2 (https=) |
| IL (1) | IL315659A (https=) |
| MX (1) | MX2024011244A (https=) |
| TW (1) | TW202345867A (https=) |
| WO (1) | WO2023176862A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026052079A1 (zh) * | 2024-09-07 | 2026-03-12 | 苏州瑞博生物技术股份有限公司 | 寡核苷酸、寡核苷酸缀合物及组合物和用途 |
| WO2026052078A1 (zh) * | 2024-09-07 | 2026-03-12 | 苏州瑞博生物技术股份有限公司 | 寡核苷酸、寡核苷酸缀合物及组合物和用途 |
| US12454693B1 (en) * | 2024-09-27 | 2025-10-28 | Dexcel Pharma Technologies Ltd. | Nucleic acids for inhibiting expression of transferrin receptor 2 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
| JPH0787982A (ja) | 1993-01-29 | 1995-04-04 | Sankyo Co Ltd | 修飾オリゴデオキシリボヌクレオチド |
| US6096881A (en) | 1997-05-30 | 2000-08-01 | Hybridon, Inc. | Sulfur transfer reagents for oligonucleotide synthesis |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| ES2234563T5 (es) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| TWI455944B (zh) * | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
| US20110196141A1 (en) | 2009-09-07 | 2011-08-11 | Council Of Scientific & Industrial Research | Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides |
| WO2011072082A2 (en) | 2009-12-09 | 2011-06-16 | Nitto Denko Corporation | Modulation of hsp47 expression |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012074038A1 (ja) | 2010-12-02 | 2012-06-07 | 第一三共株式会社 | 修飾１本鎖ポリヌクレオチド |
| EP2723861A4 (en) | 2011-06-21 | 2014-12-10 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION |
| SI3366775T2 (sl) | 2011-11-18 | 2025-12-31 | Alnylam Pharmaceuticals, Inc. | Modificirana sredstva RNAI |
| EP3730618A1 (en) | 2011-11-18 | 2020-10-28 | Alnylam Pharmaceuticals, Inc. | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
| WO2014109384A1 (ja) | 2013-01-10 | 2014-07-17 | 塩野義製薬株式会社 | 架橋型核酸誘導体の製造方法 |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| TW201534578A (zh) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| JP6482475B2 (ja) | 2014-01-07 | 2019-03-13 | レナセラピューティクス株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| CN106795200B (zh) | 2014-10-10 | 2020-06-19 | 豪夫迈·罗氏有限公司 | Galnac亚磷酰胺、其核酸缀合物及其用途 |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| US20170034685A1 (en) | 2015-07-27 | 2017-02-02 | Qualcomm Incorporated | Lte-d2d discovery in the unlicensed band |
| KR20180031025A (ko) | 2015-07-31 | 2018-03-27 | 아크투루스 쎄라퓨틱스, 인크. | 약물 전달을 위한 다중 리간드 제제 |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| BR112018003910B1 (pt) | 2015-11-16 | 2022-03-22 | F. Hoffmann-La Roche Ag | Derivado de fosforamidita galnac, processo para a preparação de um derivado de fosforamidita galnac de fórmula i e uso dos derivados de fosforamidita galnac de fórmula i |
| AU2017213404A1 (en) | 2016-01-29 | 2018-09-20 | Kyowa Kirin Co., Ltd. | Nucleic acid conjugate |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| KR102398295B1 (ko) | 2018-03-09 | 2022-05-17 | 다이이찌 산쿄 가부시키가이샤 | 당원병 Ia형 치료약 |
| US11279930B2 (en) * | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| IL291251B1 (en) | 2019-09-10 | 2026-02-01 | Daiichi Sankyo Co Ltd | Oligonucleotide-galnac conjugate for targeted delivery to the liver and method for its production |
-
2023
- 2023-03-15 EP EP23770815.1A patent/EP4495240A1/en active Pending
- 2023-03-15 WO PCT/JP2023/009973 patent/WO2023176862A1/ja not_active Ceased
- 2023-03-15 IL IL315659A patent/IL315659A/en unknown
- 2023-03-15 CN CN202380027653.6A patent/CN118891366A/zh active Pending
- 2023-03-15 TW TW112109503A patent/TW202345867A/zh unknown
- 2023-03-15 AU AU2023234185A patent/AU2023234185A1/en active Pending
- 2023-03-15 KR KR1020247034184A patent/KR20240161967A/ko active Pending
- 2023-03-15 JP JP2024508204A patent/JPWO2023176862A1/ja active Pending
- 2023-03-15 US US18/846,469 patent/US20250188478A1/en active Pending
-
2024
- 2024-09-12 MX MX2024011244A patent/MX2024011244A/es unknown
- 2024-10-08 CO CONC2024/0013601A patent/CO2024013601A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7660154B2 (ja) | アンジオポエチン様３（ＡＮＧＰＴＬ３）の発現を阻害するためのＲＮＡｉ剤および組成物、ならびに使用方法 | |
| JPWO2023176862A5 (https=) | ||
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| CN118879696A (zh) | 用于抑制载脂蛋白C-III(APOC3)的表达的RNAi试剂和组合物 | |
| TW201639962A (zh) | Ｒｎａ干擾劑 | |
| JP2021502120A (ja) | 細胞におけるｌｐａの発現を抑制するための核酸 | |
| CN110832077B (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| JP2021533804A5 (https=) | ||
| US20080214436A1 (en) | Methods and compositions for the treatment of cancer or other diseases | |
| CN108064313A (zh) | 用于抑制因子xii的基因表达的组合物和方法 | |
| JP2020503070A (ja) | α−１アンチトリプシン（ＡＡＴ）ＲＮＡｉ剤、ＡＡＴ ＲＮＡｉ剤を含む組成物、及び使用方法。 | |
| JP2022507282A (ja) | 細胞におけるｌｐａの発現を抑制するための核酸 | |
| JPWO2018003739A1 (ja) | 機能的リガンドを含む核酸複合体 | |
| CN118891366A (zh) | 抑制转铁蛋白受体2的表达的siRNA | |
| CN121294438A (zh) | 高级rna靶向(arnatar) | |
| EP3697909A1 (en) | Rnai agents and compositions for inhibiting expression of asialoglycoprotein receptor 1 | |
| JP7128517B2 (ja) | 副作用を減じたアンチセンス核酸 | |
| WO2021177267A1 (ja) | ｍｉＲ－３３ｂ阻害物質による動脈瘤の予防または治療 | |
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| JPWO2003025173A1 (ja) | Ｃ型肝炎ウイルスに対する新規なアンチセンスオリゴヌクレオチド誘導体 | |
| RU2024129248A (ru) | МиРНК, ПОДАВЛЯЮЩАЯ ЭКСПРЕССИЮ РЕЦЕПТОРА ТРАНСФЕРРИНА 2 | |
| TW202528539A (zh) | 抑制受磷蛋白之表現的siRNA | |
| WO2020262555A1 (ja) | 核酸医薬副作用軽減剤、該核酸医薬副作用軽減剤を含む医薬組成物、並びに核酸医薬の副作用惹起性を軽減する方法 | |
| JPWO2002006297A1 (ja) | ウイルムス腫瘍遺伝子に対する新規なアンチセンスオリゴヌクレオチド誘導体 |